Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China

被引：6

作者：

Meng, Fan-Ya ^{[1
,2
,3
]}

Sun, Yong ^{[3
]}

Shen, Yong-Gang ^{[3
]}

Pan, Hai-Feng ^{[1
,2
]}

Tang, Ji-Hai ^{[3
]}

Wang, Bin-Bing ^{[3
]}

Wu, Chang-Hao ^{[4
]}

Ye, Dong-Qing ^{[1
,2
]}

机构：

[1] Anhui Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hefei, Anhui, Peoples R China

[2] Key Lab Major Autoimmune Dis, Hefei, Anhui, Peoples R China

[3] Anhui Ctr Dis Control & Prevent, Dept Immunizat & Prevent, Hefei, Anhui, Peoples R China

[4] Univ Surrey, Fac Hlth & Med Sci, Guildford, Surrey, England

来源：

PLOS ONE | 2017年 / 12卷 / 02期

基金：

英国生物技术与生命科学研究理事会;

关键词：

EVENT FOLLOWING IMMUNIZATION; CASE-DEFINITION; DATA-COLLECTION; FEBRILE SEIZURES; GUIDELINES; ELIMINATION; CHILDREN; AGE; FEVER;

D O I：

10.1371/journal.pone.0172108

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The safety of measles vaccination is of great interest and importance to public health practice and the general society. We have analyzed the adverse events following immunization (AEFIs) of currently used measles-containing vaccines (including live attenuated measles vaccine, live attenuated measles and rubella combined vaccine, live attenuated measles and mumps combined vaccine, live attenuated Measles, Mumps and Rubella Combined Vaccine) in Anhui Province, China. From 2009 to 2014, 9.9 million doses of measles-containing vaccines were administrated and 1893 AEFIs were found (191.4 per million doses), of which, 33 serious AEFIs (3.3 per million vaccine doses) were reported. 59.4% (1124 cases) were male cases, and 85.1% (1611 cases) occurred in persons aged < 1 year. 93.3% (1766 cases) occurred at the first dose of vaccination and 95.9% (1815 cases) were found within 3 days after vaccination. This study presents up-to-date data and suggests that the measles-containing vaccines used in Anhui Province of China are safe.

引用

页数：11

共 50 条

[21] POST-MARKETING SURVEILLANCE OF DRUGS
LAWSON, DH
[J]. BRITISH MEDICAL JOURNAL, 1979, 2 (6189): : 546 - 546
[22] Post-marketing surveillance of sertindole
Toumi, M
[J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2002, 6 : S33 - S35
[23] Post-marketing surveillance of buprenorphine
Ray, R
Pal, H
Kumar, R
Maulick, P
Mangla, R
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (09) : 615 - 619
[24] PROBLEMS OF POST-MARKETING SURVEILLANCE
CASTLE, WM
NICHOLLS, JT
DOWNIE, CC
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 16 (06) : 581 - 585
[25] Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention
Moro, Pedro L.
Li, Rongxia
Haber, Penina
Weintraub, Eric
Cano, Maria
[J]. EXPERT OPINION ON DRUG SAFETY, 2016, 15 (09) : 1175 - 1183
[26] POST-MARKETING SURVEILLANCE OF DRUGS
HARCUS, AW
WARD, AE
SMITH, DW
[J]. BRITISH MEDICAL JOURNAL, 1979, 2 (6194): : 867 - 867
[27] POST-MARKETING DRUG SURVEILLANCE
WALDEN, RJ
PRICHARD, BNC
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 6 (03) : 191 - 192
[28] A PRESCRIPTION FOR POST-MARKETING SURVEILLANCE
ROUTMAN, KD
[J]. DRUG & COSMETIC INDUSTRY, 1980, 126 (06): : 60 - 64
[29] Social Media Listening for Routine Post-Marketing Safety Surveillance
Gregory E. Powell
Harry A. Seifert
Tjark Reblin
Phil J. Burstein
James Blowers
J. Alan Menius
Jeffery L. Painter
Michele Thomas
Carrie E. Pierce
Harold W. Rodriguez
John S. Brownstein
Clark C. Freifeld
Heidi G. Bell
Nabarun Dasgupta
[J]. Drug Safety, 2016, 39 : 443 - 454
[30] Efficacy and safety of nateglinide in post-marketing surveillance studies in Japan
Damholt, BB
Golor, G
Wierich, W
Pedersen, PC
Ekblom, M
Zdravkovic, M
[J]. DIABETES, 2005, 54 : A114 - A114

← 1 2 3 4 5 →